Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited Price to Earnings Ratio (P/E) on January 14, 2025: 1,648.10

Piramal Pharma Limited Price to Earnings Ratio (P/E) is 1,648.10 on January 14, 2025, a 1,772.67% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Piramal Pharma Limited 52-week high Price to Earnings Ratio (P/E) is 2,149.86 on November 06, 2024, which is 30.44% above the current Price to Earnings Ratio (P/E).
Piramal Pharma Limited 52-week low Price to Earnings Ratio (P/E) is -100.52 on January 31, 2024, which is -106.10% below the current Price to Earnings Ratio (P/E).
Piramal Pharma Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 1,123.63.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years